The G protein coupled receptors (GPCRs) are proteins located in the cell membrane. Their function is to transmit a stimulus from the outside to the inside of the cell. The 363 non sensitive GPCRs of the human genome constitute the largest family of therapeutic targets studied by the pharmaceutical industry. 46 of those receptors are targeted by at least one prescribed drug and 70 GPCRs by at least one drug candidate in clinical development. Thereby, GPCRs represent a significant market potential.
Theranyx shows a great interest in the GPCRs and has produced a collection of 250 receptors of this family. Our platform has generated functional antibody fragments modulating the activity of several GPCRs.
Theranyx is particularly interested in GPCRs that are found to be overexpressed in tumor cells. A Therabody™ generated against one of these GPCRs could be applied in one of four different ways:
- For the validation of the implication of the targeted GPCRs in tumor growth.
- For diagnostic application such as in vivo imaging or immunohistochemistry on biopsies
- For therapeutic application once the anticancer property of the Therabody™ is demonstrated
- As a vector in antibody drug conjugate (ADC) applications to confer greater specificity in the delivery of cytotoxic drugs to tumor cells.